Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis.

Lieberman JA.

J Clin Psychiatry. 1996;57 Suppl 11:68-71. Review.

PMID:
8941173
2.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

3.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

4.

Clinical experience in developing treatment regimens with the novel antipsychotic risperidone.

Kopala LC.

Int Clin Psychopharmacol. 1997 Sep;12 Suppl 4:S11-8. Review.

PMID:
9352341
5.

Atypical antipsychotic agents: a critical review.

Worrel JA, Marken PA, Beckman SE, Ruehter VL.

Am J Health Syst Pharm. 2000 Feb 1;57(3):238-55. Review.

PMID:
10674777
6.
7.

Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia.

Stimmel GL, Gutierrez MA, Lee V.

Clin Ther. 2002 Jan;24(1):21-37. Review.

PMID:
11833834
8.

Management of treatment-resistant patients with schizophrenia.

Marder SR.

J Clin Psychiatry. 1996;57 Suppl 11:26-30. Review.

PMID:
8941168
9.

[Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].

Haefliger T, Bonsack C.

Encephale. 2006 Jan-Feb;32(1 Pt 1):97-105. French.

PMID:
16633296
10.

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.

J Clin Psychiatry. 2003;64 Suppl 12:5-19.

11.

[Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].

Mazza M, Tozzini C, Giosué P, De Risio A, Palmucci M, Roncone R, Casacchia M.

Clin Ter. 2003 Mar-Apr;154(2):79-83. Italian.

PMID:
12856365
12.

A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.

Akdede BB, Anil Yağcioğlu AE, Alptekin K, Turgut TI, Tümüklü M, Yazici MK, Jayathilake K, Tunca Z, Göğüş A, Meltzer HY.

J Clin Psychiatry. 2006 Dec;67(12):1912-9.

PMID:
17194269
13.

[Leponex, 10 years after -- a clinical review].

Llorca PM, Pere JJ.

Encephale. 2004 Sep-Oct;30(5):474-91. Review. French.

PMID:
15627052
14.

Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.

Zink M, Mase E, Dressing H.

Hum Psychopharmacol. 2004 Jun;19(4):271-3.

PMID:
15181656
15.

Novel pharmacological approaches to the treatment of schizophrenia.

Fink-Jensen A.

Dan Med Bull. 2000 Jun;47(3):151-67. Review.

PMID:
10913983
16.

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.

Zink M, Kuwilsky A, Krumm B, Dressing H.

J Psychopharmacol. 2009 May;23(3):305-14. doi: 10.1177/0269881108089593. Epub 2008 Jun 18.

PMID:
18562423
17.

[The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].

Faludi G.

Neuropsychopharmacol Hung. 2005 Mar;7(1):22-7. Review. Hungarian.

PMID:
16167464
18.

Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia.

Cooper D, Moisan J, Grégoire JP.

J Clin Psychiatry. 2007 Jun;68(6):818-25.

PMID:
17592904
20.

Recent advances in the pharmacotherapy of schizophrenia.

Borison RL.

Harv Rev Psychiatry. 1997 Jan-Feb;4(5):255-71. Review.

PMID:
9385002

Supplemental Content

Support Center